This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Good day, ladies and gentlemen, and welcome to the ISO-RAE Inc. Q1 FY 2023 call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Mark Levin. Sir, the floor is yours.
spk06: Thank you, operator. Good afternoon, and thank you for joining us today for the ISO-RAE Fiscal First Quarter 2023 earnings call for the quarter ended September 30, 2022. Before we get started, I will take a few minutes to read the forward-looking statement. Certain statements within this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. When used in this conference call, words such as will, believe, anticipate, encourage, and similar expressions as they relate to the company or its management, as well as assumptions made by and information currently available to the company's management, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and beliefs and about future events as of today, November 10, 2022, including statements regarding the anticipated synergies and benefits of the proposed merger with viewpoint molecular targeting. As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances, and the company undertakes no obligation to, and expressly disclaims any obligation to update or alter its forward-looking statements, whether resulting from such changes, new information, subsequent events, or otherwise. Risk and uncertainties include whether the proposed merger is completed, and if so, whether the anticipated benefits of the merger are realized, whether an event occurs, including an event with a material adverse effect, or a condition to closing the merger is not satisfied, such as failure to obtain approval from ISARAY stockholders that results in a failure to complete the merger, whether ISARAY and Viewpoint are able to successfully integrate their businesses, and whether restrictions on ISARAY's business during the pendency of the merger harm our business. Additional information concerning forward-looking statements is contained under the headings of safe harbor statement, and risk factors listed time to time in the company's filings with the Securities and Exchange Commission. We will begin today's call with Lori Woods, ISRA's Chief Executive Officer, and Tay Spohr, Chief Executive Officer of Viewpoint Molecular Targeting. And then Jonathan Hunt, ISRA's Chief Financial Officer, will discuss the fiscal first quarter 2023 financial results. Following their prepared remarks, we will take questions from our analysts and institutional investors. I will now turn the call over to Lori.
spk04: Thank you, Mark. Good afternoon, and thank you for joining us today for ISRA's Fiscal First Quarter 2023 Earnings Conference Call for the quarter ended September 30, 2022. Joining us again today is Tase Spohr, Chief Executive Officer of Viewpoint Molecular Targeting. Together we will be discussing the proposed merger of our two companies and why we believe the combination represents an attractive opportunity for investors. Following our prepared remarks, our Chief Financial Officer, Jonathan Hunt, will provide a more detailed review of our fiscal first quarter financial results. Before we discuss the proposed merger with Viewpoint, I have a brief update on our isotope supply and our attendance at ASTRO, the American Society of Therapeutic Radiation Oncologists. The isotope supply chain issues that impacted us during the first quarter of 2023 have been resolved. The second reactor that was down for planned maintenance came back online in early September and has supplied all of our isotope needs since then. Additionally, I am happy to report that the other reactor that experienced the unplanned disruption is back online and we anticipate receiving our first isotope shipment from it early next month. I am also pleased to update you on our recent participation at ASTRO's annual meeting. It was noteworthy for a few reasons. This was the first ASTRO meeting since the pandemic that had a significant in-person attendance. It was very gratifying to be able to connect with our customers and colleagues again and to see the interest from physicians in the development of theranostic radiopharmaceuticals such as Lead 212. We participated in discussions and heard from many different constituents that the time has come for this technology to make significant inroads in the treatment of a variety of cancers. We had very interesting discussions with leading research institutions on proposed clinical trial work, both with cesium-131 and lead-212. We're very excited about the follow-up planned with these institutions. Now, turning to the proposed merger. We believe that the proposed merger with Viewpoint presents an exciting transformational opportunity for ISOR-A and our stakeholders. To fully appreciate what this opportunity represents, I believe it is helpful to look at this merger from the perspective of where we've been and where we stand now. IceRay has been a company founded on the merits of cesium-131 brachytherapy for the treatment of cancers. As we evolved, our expansion beyond prostate cancer to the treatment of other cancers throughout the body reflected a strategic approach to growing the company and treatment opportunities for patients and their doctors. When we announced the viewpoint transaction, I shared with you that we had undertaken a rigorous evaluation process, bringing in industry experts to help us analyze our target markets of radiation, theranostic radiopharmaceuticals, and imaging technologies. Our research and due diligence was based on our determination to continue to build on Isoray's leadership role in brachytherapy while positioning ourselves at the forefront of the next major advancements in cancer treatment. At the same time, we were equally determined to remain committed to continuing to bring precise, personalized, targeted solutions that advance options for patients. The proposed merger does just that, as we believe it provides a pipeline of future products supporting that commitment to our patients, assuring the continued growth of Ice Array and increasing shareholder value. We believe the merger represents a pivot for Ice Array going forward, given the early-stage nature of Viewpoint's Theranostic radiopharmaceutical portfolio. A significant amount of the combined company's resources and investments going forward will be focused on the development of Viewpoint's pipeline. We believe that based on the compelling results of the early stage data and the overall market opportunity that exists for Viewpoint's portfolio, investing in the development of Viewpoint's product pipeline will be richly rewarded over time. Those rewards will come as clinical milestones are achieved and innovative products are brought to market. Now I will turn the call over to Tace to talk further about the recent developments at Viewpoint and the opportunities that we believe their pipeline represents.
spk09: Thanks, Lori. The past year has been very exciting for Viewpoint. Highlights of key developments for the past few months include important progress on our clinical stage, theranostic radiopharmaceuticals, additional grant awards, new compound pipeline progress, increased manufacturing capacity, and the ability to attract really strong talent. These achievements come against the backdrop of increasing deal flow and product approvals in the radiopharmaceutical space. It is anticipated that the global radiopharmaceuticals market will grow again by about 7% in 2021 to reach about US $6 billion. By 2031, It is projected that radiotherapeutics will represent around 75% of the estimated $33 billion nuclear medicine market, with a compound annual growth rate of 18%, which exceeds that expected for prescription oncology drugs, according to MedRay's Intel report from last year. The magnitude of this significant growth is translating to major M&A activities, with over $17 billion of transactions in the past seven years. These include Bayer's acquisition of Algida for its prostate cancer treatment, which is radium labeled Zepifo. That was a $2.9 billion acquisition. Novartis acquired Advanced Accelerated Applications in its neuroendocrine tumor treatment, which is lutecin-177 labeled Lutathera in January 2018 for a total of $3.9 billion. And again, Novartis in 2018 bought up Endocyte with its prostate cancer drug, which is lutecin-177 labeled PSMA for $2.1 billion. Our drug in development for the treatment of melanoma, the MTO1, is breaking new ground based on some remarkable data in imaging and therapy. We did animal experiments using the drug on its own, known as monotherapy, as well as in combination with other approved cancer drugs. Monotherapy gave very strong results in the highly aggressive form of the melanoma. When used in combination, though, we saw some of the animals getting complete responses, meaning that the disease appeared to have been completely managed and they were able to live out the remainder of their lives. The data has been published and is receiving great critical review. In fact, it led us to receiving a $2 million grant from the National Cancer Institute earlier this year to continue to study this extraordinary combination effect. As previously announced, Viewpoint's melanoma drug is in the clinical stage of testing, meaning we're evaluating it in humans. We had previously announced in July last year that we were going to be enrolling patients in the TMR1 study at the Mayo Clinic in Rochester, Minnesota. Enrollment in this imaging-only study has closed. We are very excited by these results, and we're moving on to the next phase of development, which will involve looking at treating patients with melanoma if they have a high expression of a specific receptor called MC1R. During the webcast we hosted on October 19th, we got a sneak peek into some of the results as presented by Dr. Jeffrey Johnson, who is the principal investigator of the study. With the various imaging versions of this drug, using both PET and SPECT imaging, We saw high levels of uptake of the drug in certain melanoma patients, but not in others. We saw a very strong safety profile in all subjects for the imaging version of this drug. We are really encouraged by the results, indicating that the scans can discriminate between patients who are unlikely to respond due to their lack of the MC1R receptor and those who could potentially benefit. So rather than taking a hit or miss approach to giving patients cancer therapies and hoping they work, A negative scan would give doctors and patients the confidence to avoid the costs and side effects of therapies with a low probability of working. We are more excited, though, about the results that showed patients who had specific melanoma tumors where the therapeutic version of the drug would be likely to give a strong response. If there's a strong image of melanoma tumors on a scan, it is logical to conclude that those tumors that light up on the scan would then be expected to be damaged or destroyed by the lead 212, the therapeutic version of the isotope in the drug. This combination of using lead-203 to image and lead-T12 to treat a tumor is a theranostic approach integrating the diagnostic and therapeutic with isotopic twins in the same element. With targeted alpha therapies, such as those being developed by Viewpoint, it is not just the tumor destruction, but something called the bystander effect, where other similar tumors in the body also get destroyed. We're working really hard right now to get a therapeutic trial in humans started over the next several months so that we can begin to share preliminary results of some of the patients receiving these targeted therapies sometime in calendar year 2023. Simply put, as we think about the progress we have made, we have seen that we can image mice and then predict which mice will respond to treatment, and we have treated mice in mono and combination therapies. In humans, we have seen which patients we can image with this specific form of melanoma, and the next step will be to confidently start to treat patients that have positive scans using the same drug that would treat them. We are working on initiating our therapeutic trials in melanoma patients with the goal to enroll and begin treating in 2023. Because these early stage trials are not blinded, we expect to be able to communicate the initial results from these studies at regular intervals throughout 2023. Changing gears, our other exciting clinical stage program, VMT AlphaNet, is being developed for use in neuroendocrine tumor treatment. Initially, we showed great results of imaging and subsequently treated animals using the drug, which uses the same isotope of lead for imaging and therapeutic treatment as the VM2O1 does for metastatic melanoma. Our scientists decided to lean in on this and do a straight head-to-head study looking at our radiopharmaceutical and the currently approved lutetium-177 dotatate, which Novartis markets as Lutathera, in comparison with leaving the animals untreated. As a reminder, Lutathera was the first radiopharmaceutical approved as a peptide receptor radionuclide therapy receiving EMA approval in 2017 and FDA approval in 2018, and is currently on track to achieve between $500 million and $1 billion in annual sales. Some highlights of our head-to-head results with lutetium dotatate were presented at the European Association of Nuclear Medicine meeting in October. The results showed that compared to doing nothing, lutetium dotatate gave the mice a significant survival benefit of a few weeks, which loosely translates into one to two years in humans. When we looked at our drug in the exact same model, however, we were able to show 100% complete response rate, which persisted for the remainder of their natural lives. We expect to have additional results from these studies, as well as the long-term safety data published in the first half of 2023. What's so exciting about this data, though, is that when Viewpoint sent this impressive animal response data to the FDA, we were granted fast track designation for this program on September 29th, 2022. This is critical because the FDA FAST Act designation is one of several approaches utilized by the FDA to expedite development and review of potential medicines for serious conditions that fulfill unmet medical needs. A potential new medicine may fill an unmet medical need by being the first therapy to address a specific serious condition, offer clinically significant advantages over other available therapies, act by a different mechanism of action than available therapies, or have a benefit in patients who are unresponsive to or intolerant of available therapy. Programs that receive FAST-TRACK designation are entitled to more frequent interactions with the FDA on drug development plans, as well as eligibility for accelerated approval, priority review, and rolling review. What this means for us is that we'll be allowed a high frequency of communication with the FDA, assuring us that questions and issues can be raised and resolved quickly. This designation often leads to early drug approval and earlier access by patients to novel therapies. And the ability to engage with the FDA in real time allows significant time savings in study conduct and adaptive design, and the ability to adjust the regulatory strategy in real time in response to patient enrollment. Another development this quarter was a recent publication which showed amazing images of our BMT AlphaNet drug in an end-stage neuroendocrine patient who is refractory after six cycles of lutecin dotadate or Lutathera. What the images showed was that the patient's tumors displayed amazing uptake at one hour and 21 hours post-injection, showing that when given as a therapy, the drug would accumulate in the tumor and nowhere else, allowing all the residual drug to be eliminated to the kidneys and into the bladder. The later scan is also helpful as it shows that over the effective two-day duration of the drug, the alpha particles, which would be delivered directly to the tumor, would not be loose in the body. That seems to be the result of some of the other approaches we have seen. With all the validating science and outside interest in BMT AlphaNet, we are working on initiating therapeutic trials with the goal to have patients enrolled and treated in 2023, just as with our melanoma program. We're also really excited about the progress of our pipeline. Viewpoint scientists have received strong validation from the melanoma and neuroendocrine programs, but the company is turning into a drug discovery platform that we believe will be extremely fruitful. We have proven that we can regularly identify a cancer target develop highly sensitive peptides to those targets on cancer cells. And then when we change isotopes, the lead C12 version, that we can destroy tumor cells that we previously identified on an imaging scan. By changing the peptides to select for other cancers, we can then target very specific diseases. Our scientists are looking at some extremely interesting cancer markers where we are now demonstrating such compelling images that we may be able to advance programs and additional indications in the clinic as early as next year. In summary, Viewpoint is finishing off this calendar year with many major pluses. We continue to attract and retain extraordinary drug development talent, people with a shared commitment to treat cancer from the inside out. Our success has continued to be recognized by being awarded incremental grants from various agencies to develop our therapies in more and more settings. We've been able to demonstrate that our platform can deliver novel therapies with long patent lines, and that by iterating our drug design, we can image cancers and then treat what we image. We have shown this by bringing to clinical trials treatments for two different cancer types, melanoma and neuroendocrine tumors. We're also looking forward to potentially expanding the platform quite rapidly with targeted alpha therapies and additional tumor types. As we look ahead to the proposed merger with ISER-A, we believe there's much to be excited about. The merger brings together both complementary skill sets and a complementary approach to treating cancer that continues the legacy of precise, personalized, targeted therapy which holds great promise for what we can build together in 2023 and beyond. With that, I'll turn it over to Jonathan.
spk10: Thank you, Tace, for that update on Viewpoint's activities. We are excited about the future of the combined companies and the markets we can reach. I am now going to discuss some of the financial information that was contained in our press release for the fiscal first quarter ended September 30, 2022, that we released a short while ago. We anticipate that our Form 10-Q will be filed with the SEC on or around November 11th. Revenue for the first quarter ended September 30, 2022 decreased to $1.72 million versus $2.56 million for the same period last year. Prostate brachytherapy revenue decreased 41% versus the first quarter of fiscal 2022. First quarter revenue was comprised of 68% for prostate brachytherapy with the balance, or 32%, of revenue attributed to other brachytherapy. The year-over-year decline in revenue was primarily the result of the isotope supply chain disruption in August that limited our ability to supply customers with product during parts of that quarter. Total other brachytherapy revenue only declined 7% versus the first quarter of fiscal 22, as cells to treat brain cancers, which include cells to GT medical technologies, increased 15% year-over-year despite the supply disruption. Gross profit as a percentage of revenues for the first quarter ended September 30, 2022, was 24.1% compared to 40.1% for the quarter ended September 30, 2021. The gross margin decline was primarily the result of the decrease in sales resulting from the lack of isotope within the quarter, which exceeded the decrease in total cost of product sales versus the year-ago quarter. First quarter gross profit dollars of $414,000 decreased 60% when compared to the same period last year. Total operating expenses consisting of research and development, sales and marketing, and general and administrative increased to $4.6 million versus $3.3 million in the first quarter of 2022. Total R&D expense increased 1% versus the comparable prior year quarter to $708,000. The increase in total research and development expenses was primarily the result of increased payroll and benefits expense due to annual merit increases and bonuses related to certain merger-related milestones, which was largely offset by lower market research and consulting expenses versus the prior year comparable period. Sales and marketing expenses increased 5% versus the comparable prior year quarter to $800,000. The increase in sales and marketing expenses was driven primarily by increased payroll and benefits expense due to annual merit increases new hires to replace sales professionals that left in fiscal 2022, and an increase in compensation payments to support sales professionals during the unplanned service disruption to ensure they did not leave due to the competitive labor market. G&A expenses of $3.1 million represented an increase of 69% versus the fiscal first quarter 2022. The year-over-year increase was primarily the result of legal expenses, third-party due diligence consulting, and investment banking expenses related to the merger with Viewpoint Molecular Targeting Inc. Also contributing to the increase were payroll and benefit expenses due to annual merit increases, bonuses related to merger-related milestones, D&O insurance expense, increased audit and legal fees, and increased travel. The first quarter net loss was $4.07 million versus a net loss of $2.24 million during the same prior year period. The net loss per basic and diluted shares was 3 cents versus the net loss of 2 cents for the prior year fiscal first quarter. Basic and diluted share results are based on weighted average shares outstanding of approximately 142.1 million at fiscal first quarter 2023 versus $141.9 million for the prior year period. As of September 30, 2022, the company had cash, cash equivalents, and short-term investments that totaled $54.1 million, or approximately $0.38 per share, compared to $55.9 million at the end of fiscal year 2022 and to June 30, 2022. The company has zero long-term debt. Shareholders' equity at the end of the fiscal first quarter 2023 totaled $57.7 million versus $61.3 million at the end of fiscal year 2022. I will now turn the call over to the operator to take questions from our analysts and institutional investors.
spk02: Ladies and gentlemen, the floor is now open for questions. If you have any questions or comments, please press star 1 on your phone at this time. We ask that while posing your question, you please pick up your handset of listening on speakerphone to provide optimum sound quality. Please hold while we poll for questions. Your first question for today is coming from Mike Ott at Oppenheimer.
spk05: Good afternoon, Laurie, Tace, and Jonathan. Thanks for taking our questions. Starting with Laurie and Jonathan, I guess good to hear the Russian reactors are back online. Wondering if it's possible to quantify the impact on the F1Q just reported, and do you see any additional impact on revenues here in F2Q?
spk10: Hi, Mike. Yeah, there was definitely that impact. It was really in the revenues. We were essentially down without much isotope through much of August and going into the beginning of September when the supply began again. In terms of the impact, there's nothing that we have quantified there, but yeah, there was a big hit. We would have expected revenue to more in line, at least with the last kind of several quarters going backwards, but that obviously did not happen due to the supply issues.
spk05: Okay, that makes sense. That's helpful, Jonathan. Thanks. And then, Taze, you mentioned in melanoma, You know, there'd be some updates coming throughout 2023. What kinds of data do you expect to report out on?
spk09: So, thanks for the question. There's a few bits of data that we expect to come out. First is on the TMR1 study. So, that TMR1 was the imaging-only one that was conducted at Mayo Clinic. So, we expect to have the full results of that study published and read out, including all the safety data. and all the comprehensive data, but we're just excited about, too, is that we're kicking off activities to begin treating patients with melanoma. And so we reasonably expect to have patients both imaged and treated with melanoma in the U.S. next year. And because the study is open label, we'll be seeing it as we go, and we'll be able to sort of communicate out how that therapy is progressing. The reason why we feel comfortable about communicating those results is that only patients with a positive scan get enrolled for the therapeutic portion. and then we'll be able to track real-time how those patients are doing.
spk05: Great. That'll be good data to see. And then, you know, Lori Ortiz, I guess, any specific customer feedback from Astro, anecdotes maybe that you can share on, you know, the reaction to the merger between ICERAN viewpoint?
spk04: So I'll take that one first. I think we both probably have some things we'd like to share with you on that. I was really interested and excited to see the interest from the radiation oncologists in the space, as the space has been primarily nuclear medicine. It was very interesting to see that it's really getting on the radar of radiation oncologists and that they're very supportive of it and looking really toward it being a big part of their practices in the future. And then, Tase, let me hand it to you.
spk09: You know, thanks, Lori. I mean, if this had been five years ago, I think we would have had a lot of raised eyebrows questioning what was going on here. But what's so exciting about this field is that these targeted radiopharmaceutical agents are proving that they're certainly robust within the U.S. framework, meaning payers are happy to reimburse for therapies that really work. The physicians know how to prescribe them and get them reimbursed and administered. Patients are benefiting from them. And as people look at the rapid uptake that they've seen with some of the pharmaceuticals today that are beta emitters, I think they're really leaning and looking forward to where we can go with the alpha emitters. So I think from the radiation oncologist perspective, I think they're really excited about this, about what we can do in an environment that's already been pre-cleared for them so that they know how to administer a drug once it gets approved.
spk05: Okay, that's great color from both of you.
spk08: Thank you. That does it for our questions.
spk02: Your next question is coming from Juan Z. at B. Riley.
spk07: Hi, thanks for taking our questions. This is Brandon Carney for Yuan. I was wondering if you could provide a little bit more commentary on what kind of synergies you expect to see between ISR's brachytherapy business and Viewpoint's targeted alpha therapy approach?
spk09: No, it's a great question. And so one of the things that we're really excited about is that as we were looking at our viewpoint growth plans for the kind of talent we were looking to attract and retain, and a lot of the roles that we were looking to do as we grow, we saw that there was an extraordinary number of really qualified people at ISARAY that we could then have combining together. I think there's economies of both scale and scope, you know, as we look at how to combine and get larger and relating across so many key functions, you know, safety, quality, regulatory. There's a whole range of them that are these functional areas where as a growing emerging company and an established company merging together, we get to take the best of both. So we're really excited to see that. On the, on the explicitly on the, you know, in the trenches, the sales reps that ISRAE has have fabulous relationships with physicians and we're growing our relationships with physicians. So it's really important to be able to reach out to the doctors on both sides. You know, it may sound like a tagline, you know, treating cancer from the inside out, but that's really what we're doing. I think for the docs, the ability to have brachytherapy and targeted alpha therapy together, seeing how excited they are.
spk07: Thanks. Thanks for the commentary. Just wondering, maybe I guess in the past I've kind of viewed brachytherapy and radiopharmaceutical therapy as competing modalities. It kind of sounds like you don't view it that way, and I was just wondering if you could speak to that a little bit.
spk09: So they're not really competing. As we look at how patients get treated and how cancers get treated, and you think about melanoma as one example, right, where you've got, if it's just something that's superficial on the skin, the dermatologist will cut it out. If it goes a little bit deeper, then they'll still try and explore and see where it gets to. But once these diseases get throughout the entire body, then you really need to kind of throw everything you can at it and deal with it the right way. There's some chemotherapy approaches that can work depending on tumor type and immunotherapy. radiation oncology. And radiation oncology now is being split into, you know, radiation from the outside in or inside out. And as we look at that, you know, there are all different ways of approaching. Combinations tend to work. We've had some great animal data showing that combinations between immunotherapy and our targeted alpha therapies really work well in the animal model, and we expect that to roll over into humans as well. But in terms of how the physicians look at it, you know, you've got this interesting intersection where you've got nuclear medicine doctors In some institutions, they're the ones that administer the injections. In other institutions, it's the radiation oncologists. These are both different physician disciplines that both really care about patients and are both really keen to give the best possible therapy. They're both set up for, you know, in terms of being licensed to administer the therapies. Each institution, though, has their own practices and policies and physician preferences. And so from our perspective, we want to make sure that we educate the market, we educate the physician base and the payer base, to allow access to as many patients as possible.
spk07: Thanks. I guess one more question on this. When you talked about alpha therapy in the past, you talked about how alpha radiation offers all these advantages over beta and gamma. And I guess I'm just wondering if you think that the gamma has a place or if there's some advantages to gamma that alpha is not addressing so it leaves space for that brachytherapy. answer?
spk09: Brachytherapy is used in a very discrete kind of tumor. For example, in the prostate, it's a very slow-growing tumor. It's got different metabolic components than a lung tumor or neuroendocrine tumor would have. With each tumor, you need to make sure you characterize the right kind of treatment, be that chemo, surgery, radiation, if the radiation is external versus internal. Right now, you've got physicians that treat prostate cancer with external beam and with brachytherapy. It depends on physician skill, what that patient looks like. We hope that every single patient that gets taken care of in the cancer setting gets a personalized approach and is really figuring out what exactly does that patient need and what exactly does that prostate need at which stage of disease. So it's really going to depend on what the patient gets. What we're adamant about with the Viewpoint technology platform is that by giving alpha particles into tumors where we know we can bind there and nowhere else, we get extraordinary results. It takes a single alpha particle to kill a cancer cell, and it's a double-stranded DNA break. That's a very, very rapid response. There are other tumor types that respond well to gamma radiation over a slower duration and period of time. Thankfully, we live in a really strong data-driven world that really depends on evidence, and it's our job to make sure we deliver that evidence. But what we've seen so far in the animal model is that alphas are having extraordinary results once the tumor is identified and matched to that targeted alpha therapy. And we're committed to developing sort of tumor by tumor exactly the right treatment for each tumor.
spk03: Thanks. That's really helpful.
spk02: Once again, if there are any questions or comments, please press star 1 on your phone at this time. Ladies and gentlemen, as a reminder, if you have any questions or comments, please press star 1.
spk01: There are no more questions at this time.
spk02: There appear to be no further questions in queue. I would like to turn the floor over to Laurie for any closing remarks.
spk04: Thank you, everybody, for joining us today. We are certainly very excited about this merger and look forward to communicating to you more and more about all the exciting news we'll have coming up. Have a great afternoon. Thanks. Bye-bye.
spk02: Thank you, ladies and gentlemen. This does conclude today's conference call. You may disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.
Disclaimer